Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: Efficacy and safety in the absence of steroids

Rheumatology

Volumn 45, Issue 7, 2006, Pages 842-846

  Quartuccio, L ^a   Soardo, G ^a   Romano, G ^a   Zaja, F ^a   Scott, C A ^a   De Marchi, G ^a   Fabris, M ^a   Ferraccioli, G ^b   De Vita, Salvatore ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cryoglobulinaemia; Nephritis; Rituximab; Steroid

Indexed keywords

ALANINE AMINOTRANSFERASE; CHLORPHENIRAMINE; COMPLEMENT COMPONENT C4; CREATININE; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; FC RECEPTOR; IMMUNOGLOBULIN M; INTERFERON; METHYLPREDNISOLONE; PARACETAMOL; PEGINTERFERON; RHEUMATOID FACTOR; RITUXIMAB; STEROID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; GENOTYPE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TOXICITY; MAINTENANCE THERAPY; MALE; MONOTHERAPY; NEUTROPENIA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; SERUM SICKNESS;

AGED; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; GLOMERULONEPHRITIS; GLUCOCORTICOIDS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, IGG; RECURRENCE; TREATMENT OUTCOME;

EID: 33745631505     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel004     Document Type: Article

References (21)

1. Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999;13:1315-49.
2. Ferri C, Greco F, Longobardo G et al. Association between hepatitis C virus and mixed essential cryoglobulinemia. Clin Exp Rheumatol 1991;9:621-4.
3. De Vita S, De Re V, Gasparotto D et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000;43:94-102.
4. Tarantino A, Campise M, Ban. G et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-23.
5. Mazzaro C, Zorat F, Caizzi M et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: A pilot study. J Hepatol 2005;42:632-8.
6. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
7. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximabin type II mixed cryoglobulinemia. Blood 2003;101:3827-34.
8. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003; 101:3818-26.
9. Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003;12:783-7.
10. Ruggenenti P, Chiurchiu C, Brusegan V et al. Rituximab in idiopathic membranous nephropathy: A one-year prospective. J Am Soc Nephrol 2003;14:1851-7.
11. Roccatello D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-61.
12. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (Rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004;43:E34-8.
13. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002;61:922-4.
14. Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20.
15. Anolik JH, Campbell D, Felgar RE et al. The relationship of RcγIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
18. Hainsworth JD. First-line maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol 2003;30(Suppl. 2):9-15.
19. Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003;12:779-82.
20. Chan OTM, Madaio MP, Shlomchik MJ. B cells are required for lupus nephritis in the polygenic, Fas-Intact MRL model of systemic autoimmunity. J Immunol 1999;163:3592-6.
21. Cohen CD, Calvaresi N, Armelloni S et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 2005;18:328-33.